title: [Evaluation of resistance to activated protein C in myocardial infarction patients].
abstract: BACKGROUND
  It is known that resistance to activated protein C (APCR), often associated with a single point mutation (Arg506-->Gln) in the coagulation factor V gene (factor V Leiden), is the most frequent inherited abnormality of blood coagulation. It plays a key role as pathogenetic factor of venous thromboembolism, but its association with an increased risk of arterial thrombosis is uncertain. Aim of the present study was to evaluate the prevalence of APCR in men, who suffered myocardial infarction more than 6 months earlier and without cardiovascular risk factors (hypercholesterolemia, smoking, diabetes, obesity and hypertension).
  
  
  METHODS
  The study was carried on 20 men aged <65 years who have suffered myocardial infarction. Twenty healthy subjetcs matched for sex and age were recruited as controls. We determined: PTT, PTT-PCA (Activated Protein C), PTT-PCA/PTT, AntiThrombin III, Protein C, Protein S, Fibrinogen, Glucose, Triglycerides, Cholesterol, HDL-C, LDL-C, APO A1, APO B100, Lp(a), oxizided LDL antibody and some components of the complement system (C3c, C4).
  
  
  RESULTS
  In the group of patients there were six subjects (30%) with APCR, while there were no subjects in the control group (0%) with APCR. Patients were subdivided into two groups: with and without APCR. Patients with APCR displayed significantly higher levels of fibrinogen (367.5+/-48.4 vs 268.3+/-37.7), LDL-C (147.0 +/-20.7 vs 125.8+/-25,6), APO B100 (133.8+/-29.8 vs 121.8+/-31.5), oxizide LDL antibody (596.8+/-357 vs 315.3+/-179.6) and C4 (45.6+/-10 vs 37.85+/-11,3). Significant positive correlations (p<0.05) were observed between PTT-PCA/PTT ratio and fibrinogen (r=0.68) and between PTT-PCA/PTT ratio and oxidized LDL antibody (r=0.61).
  
  
  CONCLUSIONS
  In conclusion, the high prevalence of APCR (30%) in our patients seems to be important in order to carry out a primary prevention of arterial thrombosis and a secondary prevention of new thromboembolic complications.
authors.affiliation: Istituto di Clinica Medica, Centro per Diagnosi delle Dislipidemie e del Rischio Trombotico, Università degli Studi, Palermo, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Avellone
authors.forename: V
authors.initials: V
authors.lastname: Di Garbo
authors.forename: D
authors.initials: D
authors.lastname: Di Raimondo
authors.forename: M
authors.initials: M
authors.lastname: Bono
authors.forename: G
authors.initials: G
authors.lastname: Abruzzese
authors.forename: R
authors.initials: R
authors.lastname: De Simone
authors.forename: G
authors.initials: G
authors.lastname: Raneli
mesh_terms: D020016:Activated Protein C Resistance / Q000453:epidemiology* / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications*; D015995:Prevalence